DailyIQ
Last updatedjust now

ISRG·Intuitive Surgical, Inc.

$414.42
+9.66 (+2.39%)
After Hours
High
$416.81
Open
$405.07
Market Cap
143.60B
52W High
$603.88
Low
$402.83
P. Close
$414.42
P/E
45.75
52W Low
$328.57
Fwd P/E
34.20
DailyIQ Est.
$507.79
Inst. Ownership
45.2%
Short Interest
2.34%
Days to Cover
3.4
Technical Score (1D)
73
BULLISH
News Sentiment
51
MIXED
On Oct 6, Jim Cramer dismissed Intuitive Surgical on his show Mad Money, citing the company’s high valuation as a key concern. He noted that ISRG’s shares were trading near $404, a 7.8% decline over the past year, and highlighted Johnson & Johnson’s superior balance sheet and free‑cash‑flow advantage as a competitive threat that could erode ISRG’s market share. The comment underscored investor worries about price pressure and rivalry from a larger, financially stronger competitor. On the same day, Zacks released an industry outlook that noted Intuitive Surgical among other medical instrument firms adopting generative AI technologies. The report outlined how GenAI is being used to create synthetic medical images, simulate disease progression, and accelerate drug development, and cited surveys indicating widespread deployment of GenAI tools in U.S. healthcare and growing use by patients for health advice. The piece did not provide specific financial or operational impacts for ISRG, merely noting its participation in the broader trend.
LOW TARGET
$324 -21.9%
2 analysts
MEAN TARGET
$477 +15.0%
16 analysts
HIGH TARGET
$685 +65.1%
23 analysts
PRICE RANGE
$324.00 - $685.00
SB / B / H / S / SS
13/16/10/1/1
DAILYIQ EST.
$507.79 (+22.4%)
Sector
Healthcare
Industry
Medical Instruments & Supplies
Exchange
NMS
Country
United States
Symbol
ISRG
Description
Intuitive Surgical is a medical technology company focused on advancing minimally invasive care through its innovative surgical systems. Its flagship product, the da Vinci Surgical System, allows surgeons to perform procedures with enhanced precision, offering a less invasive alternative to traditional surgery. Beyond surgery, Intuitive Surgical also offers the Ion endoluminal system, expanding its reach into diagnostic procedures, such as lung biopsies. The company's value proposition extends beyond its core products, providing comprehensive support through training programs, service and maintenance, and digital tools designed to optimize hospital performance. Intuitive Surgical distributes its products globally via direct sales teams, ensuring direct engagement with healthcare providers.
Bought (1Y)
0 shares
$0
Sold (1Y)
20,456 shares
$8.3M
Widman FredrikVP Corporate Controller
Option Exercise543 shares2026-09-15
Widman FredrikVP Corporate Controller
Option Exercise546 shares2026-09-15
Widman FredrikVP Corporate Controller
Sell543 shares2026-09-15
Widman FredrikVP Corporate Controller
Option Exercise543 shares2026-09-15
Widman FredrikVP Corporate Controller
Sell546 shares2026-09-15
90/ 100
Strong bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
66.0%
Net Margin
28.4%
Revenue CAGR
17.0%
Current Ratio
4.87x
Return on Equity
16.0%
Earnings Summary
Intuitive Surgical is a medical technology company that develops and sells minimally invasive surgical systems, most notably the da Vinci Surgical System, and the Ion endoluminal system for diagnostic procedures. The company operates in the medical instruments and supplies sector, serving hospitals worldwide through direct sales and comprehensive support services. In the most recent quarters, ISRG posted EPS of $2.21 in Q4 2024, $1.81 in Q1 2025, $2.19 in Q2 2025, and $2.40 in Q3 2025, all exceeding analyst estimates and indicating a steady upward trajectory. Revenue mirrored this trend, rising from $2.4135 bn in Q4 2024 to $2.5051 bn in Q3 2025, with Q4 2025 revenue of $2.8662 bn beating the $2.7988 bn estimate and Q1 2026 revenue of $2.7708 bn surpassing the $2.6179 bn forecast. Historically, the company has maintained a consistent pattern of revenue growth even when EPS margins fluctuate, with a YoY revenue increase of roughly 10% in 2025 and a 7% rise in 2026, while EPS has grown from $1.78 in Q4 2024 to $2.80 in Q2 2026, reflecting strong profitability. Recent news highlights the firm’s integration of generative AI into product development, including synthetic imaging and disease simulation, which could enhance its competitive edge as the medical instruments sector adopts AI. Analysts also note that the company’s installed base and utilization rates support continued growth, though valuation multiples have compressed; the forward price‑to‑earnings ratio remains attractive relative to historical premiums.

EPS

EstBeatMiss
$1.79$2.07$2.36$2.65$2.93Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.64 - -
Q2'26$2.55$2.80+9.8%
Q1'26$2.11$2.50+18.7%
Q4'25$2.30$2.53+9.8%
Q3'25$1.99$2.40+20.7%
Q2'25$1.92$2.19+14.1%

Revenue

EstBeatMiss
$2.4B$2.5B$2.7B$2.9B$3.0BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.0B - -
Q2'26$2.9B$2.9B+0.5%
Q1'26$2.6B$2.8B+5.8%
Q4'25$2.8B$2.9B+2.4%
Q3'25 - $2.5B -
Q2'25 - $2.4B -

Market Data

ISRG Stock Snapshot

BULLISH73/100
$415.00+$0.58 (0.1%)
Market cap
143.60B
P/E ratio
45.8
Day range
$402.83 – $416.81
News sentiment
51/100 · Neutral
Analyst target
$477.21 (+15.0%)
Consensus
Buy · 41 analysts
52-week range+26.3% off low · -31.3% from high
$328.57$603.88
Price $415.00 DailyIQ Est. $507.79

The setup on Intuitive Surgical, Inc. is the constructive kind - confirmation across timeframes, not one lone indicator. In Healthcare, names this size usually take direction from sector flows before company-level news.

Behaviour On Record

What ISRG's own history says about today's numbers

Realized volatility (21d)
30.6% 66th pct
Below its peak
-33.7%
vs 200-day average
-9.1%
Up days (1y)
47%

Intuitive Surgical, Inc. is currently running 30.6% annualised volatility over the last 21 sessions. Measured against ISRG's own 13 years of daily returns rather than a market-wide average, that is the 66th percentile — a little above its own norm, against a typical reading of 25.9%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

ISRG is trading -33.7% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -23.2%, and the deepest was -49.1% in 2022. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits -9.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 12th percentile — a narrower gap than it typically runs. Over the past year ISRG closed higher on 47% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, ISRG finished the month higher 8 of 13 times, with a median return of +4.6% and an average of +4.0%. Its strongest month historically has been November at +4.3% on average, its weakest March at -1.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: ISRG has opened more than 2% away from the prior close in 85 of 3,267 sessions (2.6% of the time), with the largest gaps running +5.4% and -9.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, ISRG moved an average of 4.6% in the session after earnings, closing higher 1 of those 3 times, with a median move of -2.8% and a largest of +7.1%.

All figures computed from 3,268 daily closes between 2013-10-07 and 2026-10-05, split-adjusted, recomputed daily. Percentiles are against ISRG's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of ISRG's sector?

Intuitive Surgical, Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (lagging).

Sector rank
#3 of 12
Sector state
Lagging
Sector rotation score
64

Options Market

What is the options market pricing for ISRG?

CallsPuts

For Intuitive Surgical, Inc.'s nearest expiry (2026-10-09, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.44), with at-the-money implied volatility around 76.9%. The options market is pricing roughly a ±4.9% move by that expiry — a range of about $372.33–$410.37.

Put/call ratio (2026-10-09)
0.44
ATM implied volatility
76.9%
Total open interest
4,205
Expected move by 2026-10-09
±4.9% ($372.33–$410.37)

Analyst Rating Changes

Are analysts turning bullish or bearish on ISRG?

Barclays most recently initiated coverage on Intuitive Surgical, Inc. to Overweight on Oct 7, 2026 with a price target of $485. Over the last 90 days, coverage has run 1 upgrade against 1 downgrade, a net mixed lean.

Latest action
Barclays — Overweight
90-day upgrades
1
90-day downgrades
1
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysInitiatedOverweight$485
Sep 8, 2026BTIGReiteratedBuy$469
Aug 12, 2026OppenheimerUpgradePerform → Outperform$500
Jul 30, 2026HSBCDowngradeBuy → Hold$931
Jul 17, 2026Raymond JamesMaintainedOutperform$577 → $483
Jul 17, 2026Piper SandlerReiteratedOverweight$580 → $470
Jul 17, 2026JP MorganMaintainedOverweight$550 → $450
Jul 17, 2026MizuhoMaintainedNeutral$500 → $400
Jul 17, 2026Wells FargoMaintainedOverweight$654 → $487
Jul 17, 2026TD CowenMaintainedBuy$520 → $485
Jul 17, 2026Evercore ISI GroupMaintainedIn-Line$430 → $375
Jul 17, 2026RBC CapitalMaintainedOutperform$600 → $575

ISRG Competitive Positioning

Intuitive Surgical, Inc. (ISRG) is tracked alongside these names in Medical Instruments & Supplies on DailyIQ — ranked by market cap, with today's move alongside.

News Sentiment Analysis

Sentiment gathered from recent headlines

51/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Barclays analyst Christopher Pasquale initiated coverage of Intuitive Surgical (ISRG) on October 7, assigning an Overweight rating. The firm set a new price target of $485, reflecting confidence in the company’s growth prospects. This upgrade signals a positive outlook for ISRG’s valuation and may influence investor sentiment.
What did this article say?
On October 6, Jim Cramer dismissed Intuitive Surgical (ISRG) on his show Mad Money, citing the company’s high valuation as a key concern. He noted that ISRG’s shares were trading near $404, a 7.8% decline over the past year. Cramer highlighted Johnson & Johnson’s superior balance sheet and free‑cash‑flow advantage as a competitive threat that could erode ISRG’s market share. The comment underscored investor worries about price pressure and rivalry from a larger, financially stronger competitor.
What did this article say?
On October 6, 2026, Zacks released an industry outlook that noted Intuitive Surgical (ISRG) among other medical instrument firms adopting generative AI technologies. The report outlined how GenAI is being used to create synthetic medical images, simulate disease progression, and accelerate drug development. It cited surveys indicating widespread deployment of GenAI tools in U.S. healthcare and growing use by patients for health advice. The piece did not provide specific financial or operational impacts for ISRG, merely noting its participation in the broader trend.
What did this article say?
Intuitive Surgical (ISRG) continues to be viewed as a wide-moat leader in robotic surgery, with robust recurring revenue potential and strong secular tailwinds. The company’s installed base and utilization rates provide a significant runway for growth, supported by ongoing product innovation and expansion into new markets. Although valuation multiples have compressed, ISRG’s forward P/E remains attractive relative to its historical premium, and analysts maintain a buy rating with expectations of mid‑teens total returns if growth outpaces conservative estimates.
What did this article say?
The Motley Fool article highlighted Intuitive Surgical (ISRG) as one of two beaten‑down stocks that could offer attractive long‑term value. It noted that ISRG’s current valuation appears low relative to its historical performance and industry peers. The piece suggested that investors might consider ISRG as a defensive play in a market perceived as overvalued. No immediate earnings surprises or guidance changes were mentioned, but the recommendation implied confidence in the company’s recovery potential.
What did this article say?
On October 5, analysts noted that Generative AI is increasingly adopted across the medical instruments sector, with ISRG positioned to benefit from this trend. The company is exploring AI-driven synthetic imaging, disease simulation, and drug discovery tools to accelerate development timelines. Regulatory developments, such as the EU AI Act and FDA discussion papers, are shaping the deployment landscape, but ISRG’s early integration efforts suggest a competitive advantage. The article highlights that over 80% of U.S. healthcare leaders have deployed GenAI use cases, indicating strong market momentum. ISRG’s involvement signals potential upside as the industry moves from experimentation to practical applications.
What did this article say?
Intuitive Surgical was evaluated at a hold rating with a fair value near $430 per share, yet the company’s valuation remains high at roughly 34 times 2027 earnings. Analysts highlighted that competitive pricing from Medtronic and Johnson & Johnson, along with potential deceleration of U.S. procedures, could compress future earnings. The firm’s recurring revenue and international growth are strong, but the risk of multiple compression outweighs the attractive cash flow and moderate procedure growth, making the current share price unattractive for new capital.
What did this article say?
Intuitive Surgical, the maker of the da Vinci robotic‑surgery system, has long dominated the market with a strong recurring revenue model. The company’s installed base grew 12% in the past year to 11,710 units, and worldwide procedures increased about 14%. However, new competitors are entering the space, prompting analysts to question whether Intuitive’s near‑monopoly will persist. Despite a 35% decline from its peak, the stock still trades near 46× earnings and a $140 billion valuation, reflecting investor confidence in its moat. The debate centers on whether the company’s market position can withstand the emerging competitive pressure.
What did this article say?
Intuitive Surgical (ISRG) shares fell 17% on Oct 2 amid concerns over slower U.S. procedure growth and affordability pressures. Analysts, however, reaffirmed a Buy rating, citing the company’s strong recurring revenue, robust cash flow, and leading position in robotic surgery. The outlook highlights the da Vinci 5 upgrade cycle, SP/Ion adoption, and expected margin improvement this year, supporting a $689.75 price target.

Technical Analysis

Real-time indicators across multiple timeframes

73
BULLISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $66.01B combined position · 11 adding, 12 trimming, 2 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy33,613,2989.70%$19.04B2026-01-29
BlackRock, Inc.▼ Sell30,024,6488.67%$11.94B2026-08-07
Invesco Ltd.▲ Buy11,843,5633.42%$4.71B2026-08-14
Geode Capital Management, LLC▲ Buy8,534,7672.46%$3.38B2026-08-12
Capital World Investors▼ Sell7,742,6812.23%$3.08B2026-08-12
Morgan Stanley▲ Buy6,561,3221.89%$2.61B2026-08-13
Norges Bank▼ Sell4,954,8741.43%$1.97B2026-08-12
JPMorgan Chase & Co▼ Sell4,247,0331.23%$1.72B2026-08-12
FMR LLC (Fidelity)▼ Sell4,251,1301.23%$1.69B2026-08-13
AllianceBernstein L.P.▼ Sell3,632,7661.05%$1.67B2026-08-14
Fisher Asset Management, LLC▲ Buy3,918,8401.13%$1.56B2026-08-04
Wellington Management Group LLP▼ Sell3,802,0031.10%$1.51B2026-08-14
Northern Trust Corp▲ Buy3,512,9961.01%$1.40B2026-08-13
Susquehanna International Group, LLP▲ Buy3,438,5950.99%$1.37B2026-08-14
Bank of America Corp▼ Sell3,403,7590.98%$1.35B2026-08-14
Goldman Sachs Group Inc▲ Buy2,920,9770.84%$1.16B2026-08-14
Baillie Gifford & Co▼ Sell2,524,4270.73%$1.00B2026-08-06
Citadel Advisors LLC• Hold2,172,4760.63%$863.95M2026-09-02
Two Sigma Investments, LP▲ Buy2,002,9280.58%$796.52M2026-08-14
Janus Henderson Group plc• Hold1,643,0600.47%$757.49M2026-05-18
Loomis Sayles & Co L P▼ Sell1,656,1560.48%$658.62M2026-08-14
Capital Research Global Investors▲ Buy1,551,6640.45%$617.07M2026-08-12
Citigroup Inc▲ Buy1,047,8670.30%$416.72M2026-08-03
Wells Fargo & Company▼ Sell1,027,5420.30%$408.63M2026-08-14
Coatue Management LLC▼ Sell793,7040.23%$315.64M2026-08-14
Q2 2026 flow:8.12M sh bought ($3.23B)2.90M sh sold ($1.17B)net +5.22M sh (+$2.06B)
Congressional Trading Activity
24 disclosed trades · ~$265.5K est. traded value · 10 buys, 14 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-01-302026-02-13
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-12-102026-01-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-11-182025-12-15
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-09-032025-10-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-07-162025-08-13
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-07-102025-08-13
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-092025-08-13
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-05-082025-06-22
Bruce WestermanHouseAR04▼ Sell$1K - $15K2025-04-212025-05-12
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-04-092025-05-14
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-04-072025-05-14
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-04-072025-05-08
Bruce WestermanHouseAR04▲ Buy$1K - $15K2025-03-032025-04-16
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-01-302025-02-11
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-01-292025-02-10
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2025-01-212025-02-10
Josh GottheimerHouseNJ05▼ Sell$1K - $15K2024-12-232025-01-14
Lisa McClainHouseMI09▲ Buy$1K - $15K2024-12-112025-08-13
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-282019-03-18
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-042019-03-01
John F. ReedSenateRI▼ Sell$1K - $15K2018-03-092018-03-12
John F. ReedSenateRI▲ Buy$1K - $15K2016-11-232016-11-28